JP2020114264A5 - - Google Patents

Download PDF

Info

Publication number
JP2020114264A5
JP2020114264A5 JP2020081118A JP2020081118A JP2020114264A5 JP 2020114264 A5 JP2020114264 A5 JP 2020114264A5 JP 2020081118 A JP2020081118 A JP 2020081118A JP 2020081118 A JP2020081118 A JP 2020081118A JP 2020114264 A5 JP2020114264 A5 JP 2020114264A5
Authority
JP
Japan
Prior art keywords
fusion protein
seq
amino acid
acid sequence
intracellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020081118A
Other languages
English (en)
Japanese (ja)
Other versions
JP7026161B2 (ja
JP2020114264A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020114264A publication Critical patent/JP2020114264A/ja
Publication of JP2020114264A5 publication Critical patent/JP2020114264A5/ja
Priority to JP2021150184A priority Critical patent/JP7441201B2/ja
Application granted granted Critical
Publication of JP7026161B2 publication Critical patent/JP7026161B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020081118A 2015-03-05 2020-05-01 免疫調節性融合タンパク質およびその使用 Expired - Fee Related JP7026161B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021150184A JP7441201B2 (ja) 2015-03-05 2021-09-15 免疫調節性融合タンパク質およびその使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562128979P 2015-03-05 2015-03-05
US62/128,979 2015-03-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017546715A Division JP6917896B2 (ja) 2015-03-05 2016-03-04 免疫調節性融合タンパク質およびその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021150184A Division JP7441201B2 (ja) 2015-03-05 2021-09-15 免疫調節性融合タンパク質およびその使用

Publications (3)

Publication Number Publication Date
JP2020114264A JP2020114264A (ja) 2020-07-30
JP2020114264A5 true JP2020114264A5 (https=) 2020-11-12
JP7026161B2 JP7026161B2 (ja) 2022-02-25

Family

ID=55587371

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017546715A Expired - Fee Related JP6917896B2 (ja) 2015-03-05 2016-03-04 免疫調節性融合タンパク質およびその使用
JP2020081118A Expired - Fee Related JP7026161B2 (ja) 2015-03-05 2020-05-01 免疫調節性融合タンパク質およびその使用
JP2021150184A Active JP7441201B2 (ja) 2015-03-05 2021-09-15 免疫調節性融合タンパク質およびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017546715A Expired - Fee Related JP6917896B2 (ja) 2015-03-05 2016-03-04 免疫調節性融合タンパク質およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021150184A Active JP7441201B2 (ja) 2015-03-05 2021-09-15 免疫調節性融合タンパク質およびその使用

Country Status (17)

Country Link
US (3) US20180044404A1 (https=)
EP (2) EP4406604A3 (https=)
JP (3) JP6917896B2 (https=)
KR (1) KR20170120701A (https=)
CN (1) CN107531805A (https=)
AU (3) AU2016226022B2 (https=)
BR (1) BR112017018919A8 (https=)
CA (2) CA3177938A1 (https=)
ES (1) ES2979088T3 (https=)
HK (1) HK1246317A1 (https=)
IL (1) IL254165B (https=)
MX (4) MX2017011201A (https=)
MY (2) MY196588A (https=)
RU (1) RU2755227C2 (https=)
SA (1) SA517382216B1 (https=)
SG (2) SG10201908203SA (https=)
WO (1) WO2016141357A1 (https=)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2948544A4 (en) 2013-01-28 2016-08-03 St Jude Childrens Res Hospital CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
DK3143134T3 (da) 2014-05-15 2021-01-04 Nat Univ Singapore Modificerede, naturlige dræberceller og anvendelser deraf
US20170335331A1 (en) 2014-10-31 2017-11-23 The Trustees Of The University Of Pennsylvania Altering Gene Expression in CART Cells and Uses Thereof
EP4406604A3 (en) 2015-03-05 2024-10-23 Fred Hutchinson Cancer Center Immunomodulatory fusion proteins and uses thereof
PL3298033T5 (pl) 2015-05-18 2023-10-30 TCR2 Therapeutics Inc. Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
DK3909972T5 (da) 2015-06-19 2024-08-05 Sebastian Kobold Pd1-cd28-fusionsproteiner og disses anvendelse i medicin
WO2017112944A1 (en) 2015-12-23 2017-06-29 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
EP3433269B1 (en) 2016-03-23 2023-09-27 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins of pd-1 and 4-1bb
WO2017201210A1 (en) 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2018009972A1 (en) * 2016-07-14 2018-01-18 Peter Maccallum Cancer Institute Chimeric antigen receptor modified t cells
CN109757103B (zh) 2016-07-14 2024-01-02 百时美施贵宝公司 针对tim3的抗体及其用途
JP7291396B2 (ja) 2016-11-22 2023-06-15 ティーシーアール2 セラピューティクス インク. 融合タンパク質を用いたtcrの再プログラミングのための組成物及び方法
US20200095547A1 (en) * 2016-12-02 2020-03-26 Darya ALIZADEH Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
ES2973548T3 (es) 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
AU2017382243A1 (en) * 2016-12-22 2019-05-02 Windmil Therapeutics, Inc. Compositions and methods for modulating the immune system
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
CN119409836A (zh) * 2017-03-17 2025-02-11 弗雷德哈钦森癌症中心 免疫调节融合蛋白及其用途
BR112019019917A2 (pt) 2017-03-27 2020-04-22 Nat Univ Singapore receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais
CA3056591A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
JP7262440B2 (ja) 2017-08-02 2023-04-21 フェインズ セラピューティクス,インコーポレーテッド 抗cd47抗体及びその使用
WO2019032628A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
US10960071B2 (en) 2017-08-07 2021-03-30 The Regents Of The University Of California Platform for generating safe cell therapeutics
EP3678677A4 (en) * 2017-09-07 2021-06-16 Cue Biopharma, Inc. Antigen-presenting polypeptides and methods of use thereof
WO2019055862A1 (en) 2017-09-14 2019-03-21 Fred Hutchinson Cancer Research Center HIGH AFFINITY T CELL RECEPTORS AND USES THEREOF
WO2019090355A1 (en) * 2017-11-06 2019-05-09 Children's National Medical Center Cells expressing antibodies and methods of treatment using the same
US11866731B2 (en) 2017-11-10 2024-01-09 Chineo Medical Technology Co., Ltd Modified immune cells and uses thereof
CN111886241A (zh) 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
EP3749685A4 (en) 2018-02-09 2021-12-22 National University of Singapore ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
CN112566650A (zh) * 2018-06-21 2021-03-26 沙塔克实验室有限公司 异二聚体蛋白及其用途
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
KR102261407B1 (ko) * 2018-10-10 2021-06-08 한국화학연구원 Hvem을 표적으로 하는 키메라 항원 수용체
US20210393692A1 (en) * 2018-11-13 2021-12-23 Memorial Sloan Kettering Cancer Center Compositions and methods for adoptive cell therapy for cancer
CA3120563A1 (en) 2018-11-26 2020-06-04 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
TWI856047B (zh) 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體t細胞調節多肽及其使用方法
GB201900858D0 (en) * 2019-01-22 2019-03-13 Price Nicola Kaye Receptors providing targeted costimulation for adoptive cell therapy
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
WO2020185796A1 (en) 2019-03-11 2020-09-17 Fred Hutchinson Cancer Research Center High avidity wt1 t cell receptors and uses thereof
CN113710697A (zh) * 2019-03-15 2021-11-26 美国政府(由卫生和人类服务部的部长所代表) 嵌合衔接子和激酶信号传导蛋白及其在免疫疗法中的用途
JP2022526504A (ja) * 2019-03-21 2022-05-25 オーエヌケー セラピューティクス リミテッド 細胞死に対する耐性が増大した改変免疫エフェクター細胞
TW202110873A (zh) 2019-04-30 2021-03-16 美商聖堤生物科技股份有限公司 嵌合受體及其使用方法
AU2020315796A1 (en) * 2019-07-19 2022-02-24 Memorial Hospital For Cancer And Allied Diseases Fusion polypeptide for immunotherapy
US12497453B2 (en) * 2019-09-27 2025-12-16 Nanjing Immunophage Biotech Co., Ltd. ROR1 specific chimeric antigen receptors and their therapeutic applications
CA3163258A1 (en) * 2019-11-27 2021-06-03 Board Of Regents, The University Of Texas System Large-scale combined car transduction and crispr gene editing of nk cells
CN115666594A (zh) * 2019-11-29 2023-01-31 苏州诺沃泰医药科技有限公司 Cart细胞在制备治疗癌症的药物中的应用
WO2021119538A1 (en) * 2019-12-11 2021-06-17 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods for manufacture and uses thereof
EP4431110A3 (en) * 2020-01-19 2025-01-15 Chineo Medical Technology Co., Ltd. Enhanced receptor for improving immune cell function
CN115298209A (zh) * 2020-02-20 2022-11-04 森迪生物科学公司 抑制性嵌合受体构造体
US20230133554A1 (en) * 2020-04-09 2023-05-04 Autolus Limited Molecule
JP7755597B2 (ja) * 2020-04-09 2025-10-16 オートラス リミテッド 細胞
GB202101491D0 (en) * 2021-02-03 2021-03-17 Autolus Ltd Molecule
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
US20230203125A1 (en) * 2020-05-22 2023-06-29 Chongqing Precision Biotech Co., Ltd. Fusion protein for reversing tumor microenvironment and use thereof
EP4182338A1 (en) 2020-07-17 2023-05-24 Instil Bio (Uk) Limited Receptors providing targeted costimulation for adoptive cell therapy
US20230295564A1 (en) * 2020-07-23 2023-09-21 Emory University Galectin-9 Specific Binding Agents for Use in Treating Cancer
WO2022056014A1 (en) 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
AU2021402100A1 (en) * 2020-12-16 2023-07-27 Orion Corporation Chimeric antigen receptor (car) spacer modifications enhance car t cell functionality
IL305795A (en) * 2021-03-10 2023-11-01 B G Negev Technologies & Applications Ltd At Ben Gurion Univ Reporter cells expressing chimeric proteins for use in determining the presence and or activity of immune barrier molecules
JP2024519945A (ja) * 2021-05-20 2024-05-21 アチェロイス バイオファーマ,インク. 免疫チェックポイント多価粒子の組成物、および使用方法
US20240360181A1 (en) * 2021-05-20 2024-10-31 Achelois Biopharma, Inc. Compositions and methods for multivalent surface display on enveloped particles
WO2022266192A1 (en) 2021-06-16 2022-12-22 Instil Bio, Inc. Receptors providing targeted costimulation for adoptive cell therapy
EP4370213A4 (en) 2021-07-16 2025-06-04 Instil Bio (Uk) Limited Chimeric molecules for targeted costimulation for adoptive cell therapy
CN113621077B (zh) * 2021-09-02 2023-01-31 山东大学 一种tim-3/cd28融合蛋白及所述融合蛋白修饰的car-t细胞
US20250144211A1 (en) * 2022-02-07 2025-05-08 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Recombinant proteins that stimulate an immune response in the presence of naturally inhibitory ligand binding
KR20250121414A (ko) * 2022-12-15 2025-08-12 칼리버 임뮤노쎄라퓨틱스, 인크. Cd47/sirp-알파 면역 체크포인트 억제제 조성물 및 그의 용도
WO2025081123A1 (en) 2023-10-12 2025-04-17 Fred Hutchinson Cancer Center Methods and compositions for improving t cell immunotherapy
EP4599843A1 (en) 2024-02-09 2025-08-13 Fundació Institut de recerca de l'Hospital de la Santa Creu i Sant Pau Car and modified cd200r combination
WO2025218739A1 (en) * 2024-04-17 2025-10-23 Jw Therapeutics R & D (Shanghai) Co., Ltd. Polypeptide systems
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1999A (en) 1841-03-12 Improvement in seed-planters
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
ATE277081T1 (de) 1994-01-11 2004-10-15 Dyax Corp Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
CA2204183A1 (en) 1994-11-01 1996-05-09 Andrew Lawrence Feldhaus Chimeric receptors for the generation of selectively-activatable th-independent cytotoxic t cells
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
ATE475669T1 (de) 2004-06-29 2010-08-15 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen
EP1699826B1 (en) 2005-01-05 2009-03-11 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
GB0504767D0 (en) 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
EP1829895A1 (en) 2006-03-03 2007-09-05 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
US8119772B2 (en) 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
US9365629B2 (en) 2007-09-24 2016-06-14 University Of Zurich Designed armadillo repeat proteins
US9163258B2 (en) * 2010-07-23 2015-10-20 Fred Hutchinson Cancer Research Center Method for the treatment of obesity
AU2011309689B2 (en) 2010-09-28 2015-01-15 Hadasit Medical Research Services & Development Ltd. Compositions and methods for treatment of hematological malignancies
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9987308B2 (en) * 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
CA2832569A1 (en) 2011-04-08 2012-10-11 Baylor College Of Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
MX2014001222A (es) 2011-07-29 2014-09-15 Univ Pennsylvania Receptores coestimuladores de cambio.
US9688740B2 (en) * 2011-10-26 2017-06-27 National Cancer Center Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy
CA2861491C (en) * 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2014106839A1 (en) 2013-01-01 2014-07-10 Kahr Medical Ltd. Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
EP2943565B1 (en) * 2013-01-14 2018-03-28 Fred Hutchinson Cancer Research Center Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
CN103965361B (zh) 2013-02-06 2018-10-30 上海细胞治疗工程技术研究中心集团有限公司 一种t细胞信号的嵌合分子转换器及其用途
US10584158B2 (en) 2013-04-17 2020-03-10 Baylor College Of Medicine Immunosuppressive TGF-β signal converter
TWI719942B (zh) 2014-07-21 2021-03-01 瑞士商諾華公司 使用cd33嵌合抗原受體治療癌症
BR112017001183A2 (pt) 2014-07-21 2017-11-28 Novartis Ag tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
SG10201913782UA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cll-1 chimeric antigen receptor
ES2841274T3 (es) * 2014-08-04 2021-07-07 Hutchinson Fred Cancer Res Inmunoterapia con células T específica para WT-1
PL3180363T3 (pl) * 2014-08-15 2020-02-28 Merck Patent Gmbh Białka fuzyjne immunoglobulin sirp-alfa
PL3560953T3 (pl) 2014-12-24 2024-05-13 Autolus Limited Komórka
WO2016118780A1 (en) * 2015-01-21 2016-07-28 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
EP4406604A3 (en) 2015-03-05 2024-10-23 Fred Hutchinson Cancer Center Immunomodulatory fusion proteins and uses thereof
DK3909972T5 (da) 2015-06-19 2024-08-05 Sebastian Kobold Pd1-cd28-fusionsproteiner og disses anvendelse i medicin
AU2016361451B2 (en) 2015-11-27 2024-01-25 Cartherics Pty. Ltd. Genetically modified cells and uses thereof
WO2017112944A1 (en) * 2015-12-23 2017-06-29 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
US10188749B2 (en) * 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
WO2017184901A1 (en) * 2016-04-20 2017-10-26 Fred Hutchinson Cancer Research Center Immunomodulatory il2r fusion proteins and uses thereof
CN119409836A (zh) 2017-03-17 2025-02-11 弗雷德哈钦森癌症中心 免疫调节融合蛋白及其用途
WO2019061012A1 (zh) 2017-09-26 2019-04-04 南京凯地生物科技有限公司 靶向cd47的特异性嵌合抗原受体t细胞的制备及其应用
CN110330567B (zh) 2019-07-02 2020-11-06 南京凯地生物科技有限公司 双特异性嵌合抗原受体t细胞,其制备方法和应用

Similar Documents

Publication Publication Date Title
JP2020114264A5 (https=)
JP2022113880A5 (https=)
JP2020511136A5 (https=)
JP2018508219A5 (https=)
JP2021177771A5 (https=)
JP2021087455A5 (https=)
JP2021094037A5 (https=)
JP2020513754A5 (https=)
RU2017133637A (ru) Иммуномодулирующие слитые белки и пути их применения
JP2022534680A5 (https=)
JP2020517295A5 (https=)
JP2021500881A5 (https=)
HRP20231542T1 (hr) Kimerni antigenski receptori koji ciljaju bcma i postupci njihove uporabe
JP2021519580A5 (https=)
JP2017524367A5 (https=)
JP2020533958A5 (https=)
IL277398B1 (en) Pd-l1 binding affimers, and uses related thereto
JP2021500882A5 (https=)
JP2021514631A5 (https=)
JP2022501043A5 (https=)
JP2020513829A5 (https=)
HRP20241057T1 (hr) Kimerni antigenski receptori na osnovu jedno-domenskih antitijela i načini njihove uporabe
JP2017518071A5 (https=)
JP2018532407A5 (https=)
JP2019513394A5 (https=)